On Tuesday, Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN), added 0.65% and closed at $367.77 in the last trading session. The last trading range of the stock ranges between $361.45 and $374.13. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) recently declared financial results for the third quarter of 2016 and offered a business update.
“In the third quarter, we saw continued U.S. sales growth with EYLEA in retinal diseases and with Praluent in hypercholesterolemia,” said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. “We are preparing for a potential approval and launch for Dupixent in atopic dermatitis and continuing to advance our pipeline at all stages.”
Kronos Worldwide, Inc. (NYSE:KRO), jumped 14.48% and closed at $9.17 in the last trading session. The last trading range of the stock ranges between $8.31 and $9.46. The company’s Market capitalization is $1.11 Billion with the total Outstanding Shares of 115.89 million. Kronos Worldwide, Inc. (KRO) recently stated net income of $22.2 million, or $.19 per share, in the third quarter of 2016 contrast to a net loss of $11.8 million, or $.10 per share, in the third quarter of 2015. For the first nine months of 2016, Kronos Worldwide stated net income of $20.1 million, or $.17 per share, contrast to a net loss of $153.2 million, or $1.32 per share in the first nine months of 2015. We stated net income in the 2016 periods mainly because of higher segment profit in 2016, in addition to a non-cash deferred income tax asset valuation allowance related to our German and Belgian operations, mostly recognized in the second quarter of 2015, and an other-than-temporary impairment (OTTI) charge on our investment in a marketable equity security recognized in the third quarter of 2015. Our segment profit improved in 2016 due mainly to the net impact of higher average selling prices in the third quarter of 2016 contrast to the third quarter of 2015 (average selling prices in the first nine months of 2016 were lower as contrast to the same period in 2015), higher sales volumes, a charge associated with the implementation of certain workforce reductions (mostly recognized in the second quarter of 2015), and lower raw materials and other production costs (counting cost savings resulting from workforce reductions implemented in 2015), as talked about further below.
On the otherhand bluebird bio Inc (NASDAQ:BLUE), gained 2.67% and closed at $46.10 in the last trading session. The last trading range of the stock ranges between $44.05 and $47.25. During the 52-week trading session the minimum price at which share price traded, registered at $35.37 and reached to max level of $95.28. bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, declared that data from its ongoing clinical studies of LentiGlobin drug product in transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD) will be highlighted in oral and poster presentations at the 58th Annual Meeting of the American Society of Hematology (ASH). Preliminary data in these abstracts became available on the ASH conference website at 9:00 am ET recently.